Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study

BACKGROUND The association between liver stiffness measurements (LSM) and mortality has not been fully described. In particular the effect of LSM on all-cause mortality taking sustained virological response (SVR) into account needs further study. METHODS HIV/HCV participants in the French nation-wide, prospective, multicenter ANRS CO13 HEPAVIH cohort, with ≥1 LSM by FibroScan (FS) and a detectable HCV RNA when the first valid FS was performed were included. Cox proportional hazards models with delayed entry were performed to determine factors associated with all-cause mortality. LSM and SVR were considered as time dependent covariates. RESULTS 1,062 patients were included from 2005 to 2015 (69.8% men, median age 45.7 years (IQR 42.4-49.1)). 21.7% had baseline LSM >12.5 kPa. Median follow-up was 4.9 years (IQR 3.2-6.1). 727 (68.5%) were ever treated for HCV: 189 of them (26.0%) achieved SVR. 76 deaths were observed (26 liver-related, 10 HIV-related, 29 non-liver-non-HIV-related, 11 of unknown cause). At the age of 50, the mortality rate was 4.5% for patients with LSM ≤12.5 kPa and 10.8% for patients with LSM >12.5 kPa. LSM >12.5 kPa (adjusted Hazard Ratio [aHR] = 3.35 [2.06; 5.45], p<0.0001), history of HCV treatment (aHR = 0.53 [0.32; 0.90], p = 0.01) and smoking (past (aHR = 5.69 [1.56; 20.78]) and current (3.22 [0.93; 11.09]) versus never, p = 0.01) were associated with all-cause mortality independently of SVR, age, sex, alcohol use and metabolic disorders. CONCLUSION Any LSM >12.5 kPa was strongly associated with all-cause mortality independently of SVR and other important covariates. Our results suggest that close follow-up of these patients should remain a priority even after achieving SVR.

[1]  D. Neau,et al.  Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. , 2017, Journal of hepatology.

[2]  A. Mocroft,et al.  Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Neau,et al.  All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  P. Easterbrook,et al.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.

[5]  P. Bacchetti,et al.  Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV , 2016, AIDS.

[6]  P. Phanuphak,et al.  Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival , 2016, PloS one.

[7]  R. Weber,et al.  Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy , 2015, PloS one.

[8]  Anrs Co Hepavih Cohort Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients , 2015, AIDS.

[9]  R. Weber,et al.  High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. , 2015, Journal of hepatology.

[10]  A. Localio,et al.  Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients , 2015, Open forum infectious diseases.

[11]  M. Esteban,et al.  Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response , 2015, Digestive Diseases and Sciences.

[12]  A. Mocroft,et al.  Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals , 2015, AIDS.

[13]  Brad J. Wood,et al.  Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. , 2015, JAMA.

[14]  J. Rockstroh,et al.  Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study , 2015, The Lancet.

[15]  E. Moodie,et al.  Mortality in HIV–hepatitis C co-infected patients in Canada compared to the general Canadian population (2003–2013) , 2014, AIDS.

[16]  O. Kirk,et al.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration , 2014, The Lancet.

[17]  M. Crespo,et al.  Effects of Sustained Viral Response in Patients With HIV and Chronic Hepatitis C and Nonadvanced Liver Fibrosis , 2014, Journal of acquired immune deficiency syndromes.

[18]  P. Morlat,et al.  Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000 , 2014, AIDS.

[19]  B. Clotet,et al.  Progression of liver fibrosis in HIV/hepatitis C virus‐coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline , 2014, HIV medicine.

[20]  J. Macías,et al.  Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  B. Clotet,et al.  Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era. , 2012, AIDS research and human retroviruses.

[22]  J. Mallolas,et al.  Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Richard D Moore,et al.  Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. , 2012, JAMA.

[24]  D. Neau,et al.  The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010 , 2010, BMC infectious diseases.

[25]  Dimitris Rizopoulos,et al.  JM: An R package for the joint modelling of longitudinal and time-to-event data , 2010 .

[26]  Michael J Silverberg,et al.  Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.

[27]  J. Macías,et al.  Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus , 2009, Hepatology.

[28]  C. Tural,et al.  Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus , 2009, Hepatology.

[29]  A. Butt,et al.  Effect of hepatitis C virus and its treatment on survival , 2009, Hepatology.

[30]  Cécile Proust-Lima,et al.  Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. , 2009, Biostatistics.

[31]  Richard D Moore,et al.  Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults , 2007, AIDS.

[32]  M. Ziol,et al.  Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients , 2006, Journal of acquired immune deficiency syndromes.

[33]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[34]  G. Lüchters,et al.  Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection , 2003, The Lancet.

[35]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[36]  T. Heeren,et al.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  M. Battegay,et al.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.